Integrated Biopharma Files Q3 2025 10-Q
Ticker: INBP · Form: 10-Q · Filed: May 14, 2025 · CIK: 1016504
| Field | Detail |
|---|---|
| Company | Integrated Biopharma Inc (INBP) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biopharma
TL;DR
IBP Q3 2025 10-Q: Assets $30.3M, Liabilities $30.3M, Net Loss $0.01M. Barely afloat.
AI Summary
Integrated Biopharma Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $30,335,620 and total liabilities of $30,300,720 as of March 31, 2025. For the three months ended March 31, 2025, the company reported revenue of $0.02 million and a net loss of $0.01 million.
Why It Matters
This filing provides a snapshot of Integrated Biopharma's financial health and operational performance for the third quarter of fiscal year 2025, crucial for investors assessing its current standing.
Risk Assessment
Risk Level: medium — The company has very thin margins with total assets nearly matching total liabilities, indicating a high degree of financial risk.
Key Numbers
- $30.34M — Total Assets (As of March 31, 2025, indicating the company's total resources.)
- $30.30M — Total Liabilities (As of March 31, 2025, showing the company's total obligations.)
- $0.01M — Net Loss (For the three months ended March 31, 2025, reflecting profitability during the period.)
- $0.02M — Revenue (For the three months ended March 31, 2025, indicating sales performance.)
Key Players & Entities
- INTEGRATED BIOPHARMA INC (company) — Filer
- 20250331 (date) — Reporting Period End Date
- $30,335,620 (dollar_amount) — Total Assets as of March 31, 2025
- $30,300,720 (dollar_amount) — Total Liabilities as of March 31, 2025
- $0.02 million (dollar_amount) — Revenue for the three months ended March 31, 2025
- $0.01 million (dollar_amount) — Net Loss for the three months ended March 31, 2025
FAQ
What was Integrated Biopharma's net income or loss for the three months ended March 31, 2025?
Integrated Biopharma reported a net loss of $0.01 million for the three months ended March 31, 2025.
What were the total assets of Integrated Biopharma as of March 31, 2025?
As of March 31, 2025, Integrated Biopharma's total assets were $30,335,620.
What were the total liabilities of Integrated Biopharma as of March 31, 2025?
As of March 31, 2025, Integrated Biopharma's total liabilities were $30,300,720.
What was the company's revenue for the three months ended March 31, 2025?
The company reported revenue of $0.02 million for the three months ended March 31, 2025.
What is the fiscal year end for Integrated Biopharma?
Integrated Biopharma's fiscal year ends on June 30.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding INTEGRATED BIOPHARMA INC (INBP).